Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121628) titled 'Exhaled Breath Testing: A Non-Invasive Method for Predicting the Efficacy of Immunotherapy in Lung Cancer' on April 1.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Peking University People's Hospital
Condition:
non-small cell lung cancer (NSCLC)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-01
Target Sample Size: Cohort of Resectable Stage IB-?B NSCLC Patients Planned to Receive Neoadjuvant Immunotherapy:150;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=316707
Published by HT Digital...